key: cord-0710366-l4n9hwcx
authors: Zheng, Xueying; Luo, Sihui; Sun, Yong; Han, Mingfeng; Liu, Jian; Sun, Liangye; Zhang, Liangming; Ling, Ping; Ding, Yu; Jin, Tengchuan; Liu, Zhirong; Weng, Jianping
title: Asymptomatic patients and asymptomatic phases of Coronavirus Disease 2019 (COVID-19): a population-based surveillance study
date: 2020-06-23
journal: Natl Sci Rev
DOI: 10.1093/nsr/nwaa141
sha: 5e8cc1543e2089cb3429ab791a4cd23290335e08
doc_id: 710366
cord_uid: l4n9hwcx

In this population-based study, we identified 307 confirmed COVID-19 cases from massive surveillance, including 129,551 individuals screened at fever clinics or returning from Hubei and 3710 close contacts of confirmed COVID-19 patients. Among them, 17 patients were asymptomatic at initial clinical assessment. These asymptomatic patients on admission accounted for a small proportion of all patients (5.54%) with relatively weak transmissibility, and the detection rate was 0.35 per 100 close contacts. Moreover, the dynamics of symptoms of the 307 patients showed that the interval from symptom remission to the final negativity of viral nucleic acid was 5.0 days (IQR 2.0 to 11.0 days), with 14 patients (4.56%) having re-detectable viral RNA after discharge. Together, our findings suggested asymptomatic carriers and presymptomatic patients only accounted for a small proportion of COVID-19. Also, the asymptomatic phase in during recovery of COVID-19 urged that negativity in viral RNA is necessary as de-isolation criteria and follow-up is recommended.

was reported to range between 7% among the targeting tested Icelandic population (7) to 56% in a nursing home (3) . Other reports regarding asymptomatic cases are only single or multicentre studies of hospitalized COVID-19 patients, or series case reports (4, 5, 8, 9) . A thorough investigation on the incidence, the longitudinal clinical features and outcomes of asymptomatic patients of COVID-19 is still lacking.

Another asymptomatic phase which would impact on clinical decision and public health strategy is the duration of virus shedding after symptom relief in patients of COVID-19. There is evidence that after symptoms relieved a patient still shedded infectious virus particles (10) . Other studies showed that virus nucleic acid shedding time in COVID-19 patients could be more than a month from disease onset (11, 12) . Moreover, virus RNA was re-detected positive from the samples in some discharged patients during follow-up visits. These patients were asymptomatic, showing no signs of relapse, and had two consecutive negative results of the viral nucleic acid before discharge (13) . Although virus nucleic acid shedding does not equate to infectivity or relapse of the disease, clinicians still urged that extended isolation or observation is necessary, even if all the clinical symptoms disappeared (14) . However, the duration of such prolonged isolation has not yet reached consensus.

In this study, we aimed to analyze the asymptomatic phases in patients with SARS-CoV-2 infection among a population-based cohort in three cities Fuyang, Anqing and Lu'an in Anhui Province China. We aimed to provide profiles of asymptomatic patients on detection, description of their transmission, clinical characteristic and outcomes; and draw the dynamic picture of symptoms of COVID-19 patients based on follow-ups to reveal the time of asymptomatic virus shedding after symptom remission.

Between Therefore, these patients were all the cases incident in this epidemic wave. Table 1 and Table S1 in the Supplemental Materials summarized their clinical characteristics. We found that patients older of age, males, and patients who had preexisting conditions tended to be more severe. As for laboratory findings on admission, along with the escalation of the severity of the disease, patients were more prone to lymphopenia, showing signs of viral infection in their chest computed tomography (CT) imaging, and higher levels of inflammatory indices such as serum C-reactive protein and interleukin-6.

The median of the incubation period of all the investigated patients was 6.0 days (interquartile range [IQR] 3.0 to 10.0 days), and secondary cases had a slightly longer incubation of 7.0 days (4.0 to 12.5 days, P = 0.047, Table S1 ). The dynamics of symptoms by the severity of the disease were summarized in Figure 2 . The most common symptoms at initial assessment were fever (80.64%, 247/307) and coughing (62.87%, 193/307). As the main target of symptom-based surveillance, fever lasted for a median of 7.0 days (IQR 3.8 to 10.0 days), but coughing lasted significantly longer, for a median of 14.0 days (IQR 7.0 to 21.0 days). (Figure 2A ) Figure 2B showed that the earliest onset of relevant symptoms presented a median of 

type (see Methods for criteria of classification).

Among all 307 cases, we identified 17 asymptomatic cases on detection, who presented with no relevant symptoms at the time of the first test of SARS-CoV-2 RNA before isolation. For their exposure history, four of them returned from Wuhan during the 14 days before hospitalization, 13 had close contact with confirmed COVID-19 cases. (Figure 1 ) Based on these data, the proportion of asymptomatic patients on detection was 5.54% (17/307) , and the detection rate was 0.35% (13/3710).

As Table S3 shows, the 17 asymptomatic patients on detection aged 41.46±17.12 years, nine (52.94%) were in their middle ages (35 to 60 years).

Ten (58.52%) were female. One (patient 6) of them had gout, and one (patient 14) had hypertension, others reported no previous comorbidities. Two of them were finally categorized as mild type, and fifteen as moderate type, but none as severe type. No deaths were observed among these 17 patients.

To analyze the profile of these asymptomatic patients, we grouped the study population into four groups according to the presence of symptoms on detection: asymptomatic, afebrile but symptomatic, mild fever and moderate/high fever (Table S3) During hospitalization, all these asymptomatic patients received antiviral treatments, largely similar to the other three groups (Table S2 and Table   S4 ). But they are less likely in need of antibiotics and glucocorticoids. Laboratory test results were largely similar among the four groups (Table S3 ).

The median from admission to discharge of the asymptomatic patients on detection was 15.0 days (IQR 13.0 to 21.0 days) but can be as long as 23 days, which was similar to the other three groups. None of them had re-detectable viral nucleic acid during follow-up after discharge. Figure By analyzing the transmission and clustering data (Supplemental materials, Figure S1 ), We found that the asymptomatic patients on admission were in 11 cluster events involving 37 symptomatic patients and 17 asymptomatic patients on detection. Based on these cluster events, we estimated that one symptomatic patient would transmit the infection to a median of 1 person (IQR 0 to 2 persons; maximum eight persons), while the 17 asymptomatic patients transmitted the disease to no one, which probably due to the swift and strict quarantine policy in these cities.

We found that in the convalescent patients of COVID-19, there was a phase that their symptoms had relieved, but the results for viral RNA tests 

tests after discharge. For these 14 patients, the duration of virus RNA shedding asymptomatic phase can be up to 35.5 days (IQR 31.3 to 41.5 days).

Asymptomatic infection of SARS-CoV-2 can be infectious and may be an important underlying cause of a pandemic (16) . There are three types of different asymptomatic status of COVID-19 infection: asymptomatic carriers, presymptomatic patients in their incubation period on detection and the asymptomatic phase in the convalescent patients. In this study, based on population-based surveillance, we found that asymptomatic carriers and presymptomatic patients on detection only accounted for a small proportion of the total SARS-CoV-2 infection in cities borders Hubei during the epidemic between January and March. Under the stringent measures of social distancing, the transmission of the virus from the asymptomatic patients were well controlled. Also, we found that for all the COVID -19 patients, after they turned asymptomatic, it took approximately one week for tests of viral nucleic acid to turn negative in samples from respiratory tracts.

Overall, the proportion of asymptomatic patients on detection, including those asymptomatic carriers and presymptomatic patients, was 5.53% in our study, while 52.9% (9/17, overall 2.93%, 9/307) asymptomatic cases became symptomatic after their first viral RNA test. The proportion of asymptomatic infection was significantly higher in our study than that reported from China CDC (5.53% vs 1.2%) (17) . We also found that the proportion of presymptomatic patients on detection was higher than their counterparts among mild/moderate COVID-19 cases in Wuhan (2.93% vs 1.63%) (18) . But a recent single centre study outside Wuhan suggested the proportion of asymptomatic carriers were 4.4%, (19) similar to our study.

Of note, the detection rate of such asymptomatic infection among close contacts was similar to that in Iceland (0.35% vs 0.57 to 0.8%), but the proportion of presymptomatic infections in our study was lower than Iceland (43%) (7) and the USA nursing home (56%) (3). This could be attributed to several reasons. The targeting testing strategy of the population with a high risk of SARS-CoV-2 infection in the Icelandic study and the relatively enclosed environment of the nursing home may overestimate the incidence of presymptomatic infections. Firstly, the data in our study were collected from a population-based surveillance system, which was under a more natural circumstance and minimized the number of missing cases. Moreover, in Anhui where our study was conducted, unprecedented strict measures were taken as the public health response required since January 24, including massive surveillance, travel restriction, and strict social distancing, universal facemask-wearing during necessary outings and cession of public events.

These measures, which had been proved effective to contain the spread of the virus (20) (21) (22) , contributed to reduce the transmission of the infection and reduce the number of asymptomatic infection cases.

All these asymptomatic patients received antiviral therapy after admission to the hospital. As shown in Table S3 , such treatment did not significantly change their duration of hospitalization compared to those with symptoms on detection. Without a randomized trial, we could not determine whether the treatment had an impact on the development of symptoms.

Regarding transmissibility of the asymptomatic carriers and presymptomatic patients, some case report or case series studies provided evidence that SARS-CoV-2 virus could spread from such patients (4, 23, 24) . Survey of 77 infector-infectee transmission pairs showed that 44% of secondary cases were infected during the index infections' presymptomatic stage (25) . A study from Ningbo used a prospective design to follow up the viral load and clinical manifestations of 2,147 close contacts of symptomatic and asymptomatic COVID-19 cases. They concluded that the virus infection rates of close contacts were 6.30% with symptomatic patients and 4.11% with asymptomatic patients, respectively (26) . A recent report of the analysis 455 contacts who were exposed to an asymptomatic virus carrier also suggested the infectivity of asymptomatic carriers might be low. (27) In fact, one patient among the 17 asymptomatic patients in our study (Patient 11) was breastfeeding her 2-month old baby after she was infected with SARS-CoV-2, and she did not pass the infection to her baby. Due to the implementation of timely and effective public health interventions, we were not able to compare the transmission rates. However, based on the epidemiological data in our study, we can make a rough estimate that every asymptomatic patient on admission spread the disease to no one even under the same household, while a symptomatic onset patient could spread to a median of one secondary case and a maximum of eight. Collectively, this indicates that transmission from asymptomatic patients can be completely cut down with its lower infectivity and proper disease control measures, such like the ones that were implemented in Anhui and all over China.

Besides, we also found a potential tendency of a higher proportion of female among asymptomatic and afebrile cases on detection, which is consistent with the previous findings in Shanghai and Nanjing (4, 24) . None of these asymptomatic patients on detection in our study progressed to the severe type or died, suggesting that they were of less risk of progressing into severe status. In contrast, symptomatic patients with higher fever on

detection tend to have a shorter incubation period and increased risk of severe illness. One potential explanation would be patients asymptomatic on detection had a weaker immune response to the infection. Studies have shown that over-activated immune response could be the underlying causes of pulmonary inflammation and extensive pulmonary damage in severe cases, as well as progression and prognosis of the disease. (28) (29) (30) In our study we found that serum SARS-CoV-2 neutralizing antibodies and serum inflammatory cytokine interleukin-6 ( Table 2 and Table S3 ) levels were significantly lower in the asymptomatic patients than those symptomatic on detection at the middle of their disease course, which indicated a lower level of immune activity and might explain the difference in disease prognosis. However, we did not have data of the dynamic change in these indices, and the results should be interpreted with caution.

It is noteworthy that the asymptomatic status in the convalescent stage of a COVID-19 patient could last for seven days in mild type, and five days in moderate type, which accounted for over 80% of the total number of infection in our study. The guidelines among different countries and regions varied, but most of them suggested that patients could be discharged from the hospital when their symptoms relieved, and they should continue home isolation for 14 days (31) (32) (33) (34) . In China, COVID-19 patients were discharged only if their nucleic acid tests negative for respiratory tract pathogen twice consecutively and were also asked to be home isolated for 14 days after discharge (15) . But emerging evidence showed that patients with re-detectable viral nucleic acid after discharge is not uncommon (35, 36 

Currently, temperature surveillance of fever at public places was the sole focus of infection-control strategies in some areas. In this study, we found that fever was neither the most frequent nor the symptom with the longest duration though our investigation of symptom dynamics: 83.71% of the cases had a fever at any time of their whole disease duration, but 86.97% cases had coughing. Fever lasted significantly shorter than coughing ( Figure 2B demonstrated that coughing, and perhaps in a combination of other symptoms, could develop earlier than fever. These data indicated that using fever as the only indicator to identify SARS-CoV-2 potential infection is far from sufficient. But continuous massive surveillance or lock-down would be disastrous to the social-economic status and in turn harm the disease control implementation. Together with the two asymptomatic phases discussed above, close tracing of contacts of confirmed cases, strict social distancing, universal facemask wearing would be a more feasible choice before effective vaccine emerges.

This is the first population-based surveillance study. Not only do we provide estimates for the proportion of COVID-19 patients in different asymptomatic phases, but also the dynamics of symptom in different disease severity category and their clinical outcomes. All these results provided evidence for developing strategies for disease control and treatment.

Our study has some limitations. Due to the limited sample size and the strict measures taken to contain the spread of the disease, we could not quantify the relative contributions of asymptomatic or presymptomatic patients to SARS-CoV-2 transmission. Secondly, the proportion of asymptomatic infection (including latent infection) was determined by population-based monitoring. The population-wide seroepidemiological survey has not yet been conducted. Therefore, further study is warranted to gain a better understanding.

Asymptomatic carriers and presymptomatic patients only accounted for a small proportion of COVID-19. Massive surveillance and close contact tracing could help to detect these carriers and presymptomatic patients. Asymptomatic status in the convalescent stage of a COVID-19 could last up to a week, indicating negativity in viral RNA is necessary as de-isolation criteria, and that follow-up is recommended.

This is an observational cohort study. This study is part of the project of "Construction of a bio-information platform for novel coronavirus

Since the domestic spread of SARS-CoV-2 in January 2020, strict precautionary measures had been implemented in Anhui province by the joint effort of the local governments, the centres for disease control and prevention (CDC), the health commissions, and the communities. These measures included setting up "fever clinics" dedicated to treating patients who presented with fever or any COVID-19 like symptoms (37) . In the fever clinics, all patients received tests for SARS-CoV-2 viral nucleic acid and chest CT scan. Any case with positivity in viral nucleic or chest CT abnormality would be admitted to designated hospitals for COVID-19 treatment and isolated in a single ward. Also, massive surveillance was implemented. The 

Based on the population-based surveillance system mentioned above, we acquired the information on the number of all cases who had been 

According to the National Protocol (15), SARS-CoV-2 infection was confirmed by positive results in throat swabs or respiratory specimens of real-time reverse transcription-polymerase chain reaction (RT-PCR) assay repeated twice using SARS-CoV-2 nucleic acid detection kits.

In Anhui province, to improve the quality of the detection, a two-step confirmation strategy was adopted. Samples of an individual were first tested in the laboratory of municipal CDC with two different detection kits. The municipal CDC laboratory crosschecked the results from the two kits to report a positive case. Then these positive samples were sent to the laboratory of Anhui Provincial CDC using the same procedure to test for the viral nucleic acid If the positivity could be repeated in the provincial CDC laboratory, this case was finally confirmed as positive. All suspected and confirmed cases in Anhui Province were required to go through such two-step confirmation.

We collected epidemiological and clinical data of all confirmed cases in the participating hospitals onto case report forms adapted from 

Then a third investigator validated the data by crosschecking with the record in the medical record system and communication with the physicians attending the individuals, or telephone interview of the individuals when necessary. Two independent licensed radiologists reviewed the original images of the chest CT scans. We relied on those reports which had consistent interpretation.

We collected serum samples from confirmed cases in the participating hospitals during their hospitalization.

All the confirmed COVID-19 patients admitted to the participating hospital were attended according to the National Protocol.(15) They were classified into mild, moderate and severe type of COVID-19 based on severity. Mild cases were defined as "the clinical symptoms were mild, and there was no sign of pneumonia on imaging" in align with the National Protocol. Moderate cases were those "showing fever and respiratory symptoms with radiological findings of pneumonia". Severe cases in our study were a combination of severe cases and critical cases defined by the National Protocol.

A patient should meet all the following criteria according to the National Protocol to be discharged from the designated hospital. (1) body temperature returned to normal for more than three days; (2) significant improvement of respiratory symptoms; (3) significant improvement in pulmonary imaging; (4) samples from respiratory tract were negative twice for SARS-CoV-2 nucleic acid (sampling interval being at least 24 hours).

After discharge, all patients were subjected to home isolation for another 14 days. We followed up these patients two weeks and four weeks after discharge. Fourteen of them had re-detectable viral nucleic acid in their nasopharyngeal swab samples during home isolation, and all turned negative at the end of the fourth week after discharge.

We defined incubation period as the period between the earliest exposure to the potential transmission source of SARS-CoV-2 to the onset of illness (the presence of the earliest symptom).

Suspected cases were defined in align with the criteria used in the massive surveillance. Confirmed cases were patients who were confirmed SARS-CoV-2 infection through the two-step protocol as described above. Asymptomatic cases on detection were confirmed cases without presence of any relevant symptoms at the first test (i.e., screening test) of SARS-CoV-2 RNA, including two types of patients: asymptomatic carriers and presymptomatic patients on detection. Asymptomatic carriers, i.e., patients with asymptomatic infection, were confirmed cases without any relevant symptoms, with/without a change in chest CT throughout the their disease course (infection) until their SARS-CoV-2 RNA turning negative.

Presymptomatic patients on detection were patients who were asymptomatic at their screening test of SARS-CoV-2 but later developed relevant symptoms during hospitalization. We defined asymptomatic phases as the period of time when a confirmed case who presented with no relevant symptoms, which could refer to the time between exposure to transmission source and the onset of symptom(s), or the time between overall symptom relief to the final conversion to negativity in viral RNA tests during recovery, or the duration of SARS-CoV-2 nucleic acid positivity in an asymptomatic carrier.

Based on the presence of fever on detection, we categorized the patients with symptomatic onset into three groups: afebrile, mild fever and moderate/high fever. Patients were considered afebrile on detection if their body temperature stayed under 37.3℃ before the first test of SARS-CoV-2 test. Mild fever was defined as patients who had any record of body temperature above 37.3℃, but never higher than 38.0℃ before detection.

Moderate/high fever was defined as patients who had any body temperature record above 38.0℃ before detection. Then a second antibody that recognizes IgA, IgM or IgG was added for detection of IgA, IgM and IgG, respectively. The detected chemiluminescent signal over the background signal was calculated as relative light units (RLU), COI was the ratio of RLU to statistically determined cut-off (criterion).

Then RLU was measured using a fully automatic chemical luminescent immunoanalyzer, Kaeser 1000 (Kangrun Biotech, Guangzhou, China).

Continuous variables were presented as mean ± standard deviation or median (IQR). Comparisons between groups were performed with the Student's t-test, one-way ANOVA, or Mann-Whitney U test when appropriate. Categorical variables were presented as number (%) and compared

using the χ 2 test or Fisher's exact test when appropriate. A two-sided α of less than 0.05 was considered statistically significant. Data were analyzed using the R software, version 3.6.1 (R Foundation for Statistical Computing).

We thank the patients for donating their data and sample. We thank the physicians and administrative staff for their assistance in data collection.

XZ contributed in conceptualization, study design, data collection and interpretation, and wrote the first draft. SL contributed to data and sample collection, management and interpretation, and co-wrote the first draft. XZ and SL contributed equally. YS, MH, CH, LS and LZ contributed in data collection and interpretation, administrative support, and critical discussion of the manuscript. LP, YD, TJ and SW contributed in data collection, analysis and interpretation, and discussion of the manuscript. ZL contributed in data interpretation, administrative support, and discussion of the manuscript. JW contributed in conceptualization, study design, funding acquisition, administrative support, data interpretation and critical discussion of the manuscript. 

World Health Organization. Coronavirus disease 2019 (COVID-19)

First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2)

Clinical Characteristics of Coronavirus Disease 2019 in China

Spread of SARS-CoV-2 in the Icelandic Population

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge

The enlightenment from two cases of asymptomatic infection with SARS-CoV-2: is it safe after 14 days of isolation?

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7

Covert coronavirus infections could be seeding new outbreaks

Novel Coronavirus Pneumonia Emergency Response Epidemiology T; [The epidemiological characteristics of an outbreak of

Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital

Epidemiological and clinical features of asymptomatic patients with SARS-CoV-2 infection

Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset

The effect of human mobility and control measures on the COVID-19 epidemic in China

Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China

Presumed Asymptomatic Carrier Transmission of COVID-19

Follow-up of asymptomatic patients with SARS-CoV-2 infection

Temporal dynamics in viral shedding and transmissibility of COVID-19

The epidemiological characteristics of infection in close contacts of COVID-19 in Ningbo city

A study on infectivity of asymptomatic SARS-CoV-2 carriers

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19 -first update

De-isolating Coronavirus Disease 2019 Suspected Cases: A Continuing Challenge

Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings

Discontinuation of Isolation for Persons with COVID -19 Not in Healthcare Settings -Interim Guidance

Updates on COVID-19 in Republic of Korea (as of 28 April

Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test

Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics

Procalcitonin, ng/mL, median (IQR)

Urinary protein (+ or ++), n(%)

SaO 2 Saturation of oxygen, PT prothrombin time, APTT activated partial thromboplastin time, ALT alanine aminotransferase, AST aspartate aminotransferase, BUN blood urea nitrogen, CK creatinine kinase

We declare no conflict of interest.